Global Stem Cells Group Announces Opening of New Research Facility at Marmara University’s Main Campus in Istanbul, Turkey
Collaboration Set to Propel Regenerative Medicine Research and Innovation
Miami, May 20, 2023 – Global Stem Cells Group, a leading provider of regenerative medicine solutions, is thrilled to announce the opening of its state-of-the-art research facility at Marmara University’s Main Campus in Istanbul, Turkey. This collaborative endeavor between Global Stem Cells Group, ReGen (described below), and Marmara University aims to advance research and knowledge in the fields of neurological conditions, autoimmune diseases, and the validation of safety and efficacy of procedures and Cellgenic products.
ReGen, a globally recognized network of clinics and a commercial partner of Global Stem Cells Group, is dedicated to providing cutting-edge cellular therapies that enhance patient well-being. This joint effort between ReGen, Global Stem Cells Group, and Marmara University seeks to drive research and innovation in cell therapy and tissue engineering.
Renowned for its commitment to excellence in education, research, and innovation, Marmara University provides an exceptional foundation for Global Stem Cells Group’s new research facility. With a strong emphasis on interdisciplinary collaboration and forefront research, Marmara University has emerged as a hub of intellectual discovery and academic achievement. The University’s renowned faculty and state-of-the-art infrastructure make it an ideal partner for Global Stem Cells Group in driving advancements in regenerative medicine.
By establishing this collaborative research facility at Marmara University, Global Stem Cells Group plans to access to the university’s wealth of expertise and resources, enabling the organization to undertake extensive clinical studies and groundbreaking research. Together, they will focus on addressing the challenges posed by neurodegenerative diseases and other medical conditions, aiming to develop innovative treatments and therapies that can significantly improve patient outcomes.
“Both Global Stem Cell Group and its commercial partner, ReGen, are thrilled to establish our new research facility in partnership with Marmara University.” Benito Novas, CEO of Global Stem Cells Group, expressed his enthusiasm for the collaboration. “This collaboration holds significant meaning for us, particularly in terms of the Cellgenic brand,” he added.
The Cellgenic product line encompasses a range of point-of-care regenerative medicine products, including autologous and allogeneic therapies, as well as exosomes. After examining the independent testing and validation of these products employed by Marmara University, Global Stem Cell Group is confident in the University’s quality and effectiveness.
The newly inaugurated research facility is expected to serve as a hub for extensive clinical studies on various medical conditions, with a particular focus on neurodegenerative diseases and ailments treatable through cell therapy and tissue engineering. This research is expected to contribute to the advancement of medical knowledge and the development of innovative treatments that have the potential to transform the lives of patients worldwide.
Global Stem Cells Group and its commercial partner, ReGen, extend their gratitude to Marmara University for its unwavering commitment to advancing regenerative medicine research and innovation. The collaboration between Global Stem Cells Group, ReGen, and Marmara University signifies what the parties believe is a significant milestone in the field of regenerative medicine, combining the expertise and resources of three leading institutions to drive breakthrough discoveries and shape the future of healthcare.
For more information about Global Stem Cells Group and its regenerative medicine solutions, please visit https://www.stemcellsgroup.com/.
About Global Stem Cells Group
Global Stem Cells Group is a leading provider of regenerative medicine solutions, dedicated to advancing healthcare through innovative therapies. With a global presence and a multidisciplinary team of experts, the organization strives to harness the potential of stem cells and regenerative medicine to improve patient outcomes across various medical fields. Through its extensive network of clinics, research facilities, and training centers, Global Stem Cells Group is committed to pushing the boundaries of regenerative medicine and making a positive impact on global healthcare.
About ReGen
ReGen is a renowned network of clinics and commercial partner of Global Stem Cells Group worldwide, offers cutting-edge cellular therapies to enhance the well-being of its patients. ReGen aims to drive research and innovation in cell therapy and tissue engineering together with Global Stem Cells Group and Marmara University.
About Marmara University
Marmara University is a prestigious educational institution renowned for its commitment to excellence in education, research, and innovation. With a strong emphasis on interdisciplinary collaboration and cutting-edge research, Marmara University has emerged as a hub of intellectual discovery and academic achievement. The university’s renowned faculty and state-of-the-art infrastructure make it an ideal partner for Global Stem Cells Group in driving advancements in regenerative medicine.
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Releases
Global Stem Cells Group Announces Training in Lima, Perú
MIAMI,Florida—The International Society for Stem Cell Application (ISSCA) has announced plans to hold a Cell therapy Certification training course for qualified physicians in Lima on December 09 and 10, 2022.
Each participating physician obtains the intellectual property of 22 proprietary protocols that will them to treat degenerative and aesthetic diseases and conditions in their offices. Step-by-step videos of each protocol are provided to physicians for later referral.
Participating physicians acquire the skills necessary to offer an alternative therapy to patients with medical conditions for which no solution is currently available. ISSCA’s stem cell training course allows qualified physicians who earn certification to offer sought-after alternative treatments.
Successful completion of the ISSCA regenerative medicine certification course allows physicians to join a select group of practitioners at the forefront of medical science. Only 5 percent of physicians worldwide access to stem cell therapy studies, and so far only 0.01 percent are practicing these therapies.
The course also provides participating physicians with access to ISSCA’s online stem cell training course to review all content and procedures introduced during the two-day clinical training course, as well as patient forms and guidelines, procedures, informed consent forms, didactic lectures, training booklets, and more,
The ISSCA’s regenerative medicine protocols training course was developed for physicians and high-level practitioners to learn techniques in harvesting and reintegrating stem cells derived from patients’ adipose tissue and bone marrow.
Seating is limited to eight participants. Register today at the Lima Peru course website to secure a seat, email info@stemcellsgroup.com, or call +1 305 5605337.
About ISSCA:
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine. ISSCA serves its members through advancements made in the specialty of regenerative medicine.
The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.
As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally. The ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.
- Published in Press Releases
ISSCA to sponsor International Congress on Advanced Therapies in Medicine in Riviera Nayarit, Mexico Nov. 24-25, 2018
ISSCA will sponsor the 6th annual International Congress on Advanced Therapies in Medicine Nov. 24-25, 2018 in Riviera Nayarit.
MIAMI, July 27, 2018—For the third consecutive year the International Association for Stem Cell Application (ISSCA) will sponsor the International Congress on Advanced Therapies in Medicine 2018 on Puerto Vallarta, Mexico.
The event will feature a commercial expo with 20 with 20 booths exhibiting new products and information for physicians in the field of regenerative medicine. More than 250 physicians are expected to be in attendance.
ISSCA will present information on its Fellowship in Cell Therapy and Tissue Engineering program, a 6-day course during which a group of experienced academicians involved in stem cell transplantation present the general principles and practice of stem cell biology and evidence-based treatments to physicians looking to optimize the treatment options that benefit the health of their patients. The fellowship program will be held in Korea Oct. 22-27, 2018.
Fellowship participants will take part in a detailed program offering hands-on experience in stem cell applications and learn cell culture protocols including plating, trypsinization, harvesting, and cryopreservation, as well as an understanding and application of quality control tests including cell count, viability, flow cytometry, endotoxin, mycoplasma and sterility.
In addition, physicians participating in the ISSCA fellowship program will learn how to perform cGMP functions including cleanroom maintenance, gowning and environmental monitoring, while gaining insight on relevant applications of stem cell processing and regulations in a certified facility. ISSCA provides fellowship attendees with the tools necessary to implement regulatory and clinical guidelines when setting up a GMP facility, as well as copies of presentations, procedural protocols and all forms associated with a GMP facility provided.
Participating physicians learn to perform clinical procedures including lipoaspirate and bone marrow isolation, and reintroducing stem cells for various indications. Case books and full protocols for approximately 30 indications are also provided.
In addition, Global Stem Cells Group )GSCG) will present its stem cell processing center, a complete solution for providers to equip their practice facilities with an on-site regenerative medicine lab. Used for tissue processing, isolation, culturing and cryopreservation of stem cells, the stem cell processing center is designed to execute a state-of-the-art stem cell laboratory using the latest technology.
GSCG provides participating regenerative medicine teams with specialized training to implement high-level processes and therapies using the stem cell processing center for better clinical interpretation, better results while maintaining compliance with safety regulations and international standards.
GSCG’s stem cell laboratory solution represents a tremendous competitive advantage and differentiator that arms regenerative medicine practitioners with the ability to perform highly advanced stem cell procedures in their facilities.
The 2018 International Congress on Advanced Therapies in Medicine in Riviera Nayarit, Mexico will be held at the Hotel Krystal Grand in Nuevo Puerto Vallarta,
For more information and to register, email info@stemcellsgroup.com, or call +1305 560 5337.
About ISSCA:
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine.
ISSCA serves its members through advancements made in the specialty of regenerative medicine.ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.
As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally. Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.
About Global Stem Cells Group:
Global Stem Cells Group (GSCG) is a worldwide network that combines seven
major medical corporations. Each corporation is focused on furthering scientific and technological advancements in cutting-edge stem cell research, development, treatment, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stopepicenter for stem cell solutions that adhere to the highest medical standards.
Global stem cell’s mission is to be the largest recognized stem cell and regenerative medicine network in the world.
advanced therapies international congress
- Published in Press Releases